CD30/TNFRSF8 Antibody [Biotin]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily (1, 2). Mature human CD30 consists of a 361 amino acid (aa) extracellular domain (ECD) with six cysteine-rich repeats, a 28 aa transmembrane segment, and a 188 aa cytoplasmic domain (3). In contrast, mouse and rat CD30 lack 90 aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C‑terminal 132 aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells (4‑6). However, it is upregulated in Hodgkin’s disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity (7). CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (1, 5). CD30 signaling costimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response (8). In the absence of antigenic stimulation, it can still induce T cell expression of IL-13 (9). CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells (10, 11). In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (5, 12). An 85-90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage (13, 14). Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: Luminex Development.

Showing Publication 1 - 1 of 1.

Publication using BAF229	Applications	Species
Pavlov , Igor, Martins , Thomas B, Delgado , Julio C Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing. Clin Vaccine Immunol, 2009-07-15;16(9):1327-31. 2009-07-15 [PMID: 19605595] (Luminex Development, Human)	Luminex Development	Human

Array BAF229

• CD30/TNFRSF8 Antibodies
• CD30/TNFRSF8 Antibody Pair
• CD30/TNFRSF8 ELISA Kits
• CD30/TNFRSF8 Lysate
• CD30/TNFRSF8 Proteins
• CD30/TNFRSF8 Proteins and Enzymes
• CD30/TNFRSF8 ELISAs